Du är här

2017-09-05

Karolinska Development AB (publ): Karolinska Development company Umecrine Cognition appoints Dr. Thomas P. Blackburn to its...

STOCKHOLM - September 5, 2017. Umecrine Cognition AB, a Karolinska Development
(Nasdaq Stockholm: KDEV) portfolio company in clinical development with a
novel GABAA receptor modulator for the treatment of hepatic encephalopathy
(HE) in patients with liver disease, today announces that Dr. Thomas P.
Blackburn has been appointed as a new member of its Board of Directors and
Senior Development Adviser.

Details from the Umecrine Cognition press release follow:
Dr. Thomas P. Blackburn brings more than 40 years of experience in the
pharmaceutical and biotechnology sectors, where he has held C-level and
senior management positions at major Pharmaceuticals (ICI, Beecham/SmithKline
Beecham) and US biotech companies (Synaptic Pharmaceutical Corporation and
Helicon Therapeutics). His extensive knowledge of pre-clinical and clinical
drug development in neuroscience led to the clinical development of
antidepressant/anxiolytics (Seroxat®/Paxil®), anticonvulsants, antimigraine,
sleep and cognitive disorders (MCI, Alzheimer's Disease, ADHD), along with
commercial strategies for positioning pharmaceutical products with U.S.,
European and Japanese regulatory authorities.

Magnus Doverskog, CEO of Umecrine Cognition, said: "We are pleased to have Dr.
Blackburn join the company. He is an internationally recognized
neuroscientist, who has led companies, departments and project teams that
have identified and developed novel therapeutics. Dr. Blackburn's expertise
is in discovering innovative therapeutics and developing clinical candidates
to "proof-of-concept" and commercialization."

Dr. Blackburn commented: "I am delighted to have the opportunity to bring my
neuroscience and drug development expertise to Umecrine Cognition. The
Company's innovative therapeutic approach of restoring GABA-ergic
neurotransmission through inhibition of neurosteroid dysfunction holds great
promise for the treatment of hepatic encephalopathy in liver disease and
opens up several potential therapeutic opportunities for the treatment of
other CNS disorders representing exciting and emerging areas of unmet
clinical need and commercial opportunity."

Dr. Blackburn has authored more than 100 scientific papers, review articles,
book chapters, and is currently Reviews Editor for the British Journal of
Pharmacology. He is an inventor/co-inventor on 22 patents and holds a Ph.D.,
D.Sc., from the University of Manchester, he is an Honorary Fellow and
President Emeritus of The British Pharmacological Society, a member of the
American College of Neuropsychopharmacology and Fellow of the Royal Society
of Biology (FRSB). He also serves as a board member of Motac Neurosciences
Ltd., a company that specializes in pre-clinical models of Parkinson's
disease and neurodegeneration.

For further information, please contact:

Viktor Drvota, VD, Karolinska Development AB
Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

About Umecrine Cognition AB

Umecrine Cognition, a Karolinska Development (Nasdaq Stockholm: KDEV)
portfolio company, is developing a potential therapy that represents a new
target class relevant for several major CNS-related disorders. The primary
focus is to develop a treatment for life-threatening overt hepatic
encephalopathy and long-term treatment in covert hepatic encephalopathy in
patients with liver disease, a growing area with high unmet medical need. The
current lack of therapeutics that directly addresses the neurocognitive signs
and symptoms of Hepatic Encephalopathy makes a novel treatment likely to
become a major contribution for the treatment of this disorder. For more
information, please visitwww.umecrinecognition.com.

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying medical innovation and
investing in the creation and growth of companies developing these assets
into differentiated products that will make a difference to patients' lives
and provide an attractive return on investment to its shareholders.

Karolinska Development has access to world-class medical innovations at
leading universities and research institutes in the Nordic region, including
the Karolinska Institutet. The Company aims to build companies around
innovative products and technologies, supported by experienced management
teams and advisers, and co-funded by specialist international life science
investors, to provide the greatest chance of success.

Karolinska Development's portfolio comprises 9 companies focusing on the
development of innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by a team of investment professionals with strong
investment backgrounds, experienced company builders and entrepreneurs, with
access to a strong global network.
For more information, please visitwww.karolinskadevelopment.com

Umecrine Cognition New Board
http://hugin.info/143071/R/2131516/814466.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.